Journal of the American Academy of Child & Adolescent Psychiatry
New researchDoes ADHD Predict Substance-Use Disorders? A 10-Year Follow-up Study of Young Adults With ADHD
Section snippets
Subjects
A detailed study methodology has been previously described.26, 27 Subjects were derived from two identically designed longitudinal case-control family studies of ADHD. These studies recruited male and female probands 6 to 17 years of age with (140 boys, 140 girls) and without (120 boys, 122 girls) DSM-III-R ADHD from pediatric and psychiatric clinics. The present sample includes the 10- and 11-year follow-up for the studies of boys and girls, respectively. Of the 140 girls with ADHD and 122
Results
Overall, there were 497 probands available for study (268 cases of ADHD; mean baseline age, 10.91 ± 3.17 years) and 229 controls (mean baseline age, 11.88 ± 3.29 years). To test the first hypothesis, subjects were stratified by the presence or absence of ADHD. Subjects with ADHD without any SUD at baseline (n = 257) were significantly younger at baseline, had a significantly lower SES, and were more likely to have a parental history of an alcohol use and/or drug-use disorder compared with
Discussion
The results of this follow-up (average 10 years) study of two cohorts of children to examine early predictors for later SUD partly support our hypotheses. The present results support the hypothesis that ADHD is a risk for later SUD and the major predictive importance of early CD on subsequent SUD in ADHD youth. However, we failed to demonstrate significant associations between family, baseline cognitive, or non-CD psychiatric, treatment, subtype, or academic dysfunction and later SUD in the
References (57)
- et al.
Longitudinally predicting late adolescent and young adult drug use: childhood and adolescent precursors
J Am Acad Child Adolesc Psychiatry
(1995) - et al.
Adolescent psychopathology: IVSpecificity of psychosocial risk factors for depression and substance abuse in older adolescents
J Am Acad Child Adolesc Psychiatry
(1995) - et al.
Young adult drug use and delinquency: childhood antecedents and adolescent mediators
J Am Acad Child Adolesc Psychiatry
(1996) - et al.
Psychiatric comorbidity among adolescents with substance use disorders: findings from the MECA study
J Am Acad Child Adolesc Psychiatry
(1999) - et al.
Practice parameter for the assessment and treatment of children and adolescents with substance use disorders
J Am Acad Child Adolesc Psychiatry
(2005) - et al.
The adolescent outcome of hyperactive children diagnosed by research criteria: IAn 8-year prospective followup study
J Am Acad Child Adolesc Psychiatry
(1990) - et al.
Is ADHD a risk for psychoactive substance use disorder?Findings from a four year follow-up study
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects
J Am Acad Child Adolesc Psychiatry
(2007) - et al.
Drug use and neurobehavioral, respiratory, and cognitive problems: precursors and mediators
J Adolesc Health
(2002) - et al.
Correspondence between DSM-III-R and DSM-IV attention deficit hyperactivity disorder (ADHD)
J Am Acad Child Adolesc Psychiatry
(1997)
Substance-dependent, conduct-disordered adolescent males: severity of diagnosis predicts 2-year outcome
Drug Alcohol Depend
Further evidence of an association between adolescent bipolar disorder with smoking and substance use disorders: a controlled study
Drug Alcohol Depend
Memory functioning in polysubstance dependent women
Drug Alcohol Depend
Do executive function deficits predict later substance use disorders among adolescents and young adults?
J Am Acad Child Adolesc Psychiatry
Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions
Arch Gen Psychiatry
Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking outpatient population
Am J Addict
The worldwide prevalence of ADHD: a systematic review and meta-regression analysis
Am J Psychiatry
The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication
Am J Psychiatry
The course and outcome of ADHD
Prim Psychiatry
Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status
Arch Gen Psychiatry
Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD
J Abnorm Psychol
Controlled prospective fifteen year follow-up of hyperactives as adults: Non-medical drug and alcohol use and anti-social behaviour
Can J Psychiatry
Adult psychiatric status of hyperactive boys grown up
Am J Psychiatry
A prospective study of delinquency in 110 adolescent boys with attention deficit disorder and 88 normal adolescent boys
Am J Psychiatry
Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents?A community-based case-control study
Addiction
Developmental aspects of delinquency and internalizing problems and their association with persistent juvenile substance use between ages 7 and 18
J Clin Child Psychol
Conduct problems and attention deficit behaviour in middle childhood and cannabis use by age 15
Aust N Z J Psychiatry
Association between attention-deficit/hyperactivity disorder in adolescence and substance use disorders in adulthood
Arch Pediatr Adolesc Med
Cited by (243)
Interventions for ADHD in childhood and adolescence: A systematic umbrella review and meta-meta-analysis
2023, Clinical Psychology ReviewGender-based differences in prevalence and effects of ADHD in adults: A systematic review
2022, Asian Journal of PsychiatryExtending the two-component model of delusion to substance use disorder etiology and recovery
2022, New Ideas in PsychologyADHD medications use and risk of mortality and unintentional injuries: a population-based cohort study
2024, Translational Psychiatry
This article can be used to obtain continuing medical education (CME) category 1 credit at jaacap.org.
An interview with the author is available by podcast at www.jaacap.org.
This study was funded by grant K24 DA016264 (T.W.) and in part by a grant from the United States Public Health Service (National Institute on Child Health and Human Development) and by grant 5R01 HD-36317-07 (J.B.) and in part by a grant from the Eli Lilly and Company Foundation and the Pediatric Psychopharmacology Philanthropy Fund.
Disclosure: Dr. Wilens has received grant support from Abbott, McNeil, Eli Lilly and Co., the National Institutes of Health–National Institute on Drug Abuse, Nextwave, Merck, and Shire. He has served on the speakers' bureau for Eli Lilly and Co., McNeil, Novartis, and Shire. He has served as a consultant to Abbott, AstraZeneca, McNeil, Eli Lilly and Co., the National Institutes of Health, Nextwave, Novartis, Merck, and Shire. He receives royalties from Guildford Press. Dr. Biederman has received research support from Abbott, Alza, AstraZeneca, Bristol Myers Squibb, Celltech, Cephalon, Eli Lilly and Co., Elminda, Esai, Forest, GlaxoSmithKline, Gliatech, Janssen, McNeil, Merck, the National Alliance for Research on Schizophrenia and Depression, the National Institute on Drug Abuse, New River, the National Institute of Child Health and Human Development, the National Institute of Mental Health, Novartis, Noven, Neurosearch, Organon, Otsuka, Pfizer, Pharmacia, the Prechter Foundation, Shire, the Stanley Foundation, UCB Pharma, and Wyeth. He has served on the speakers' bureau for Fundacion Areces, Medice Pharmaceuticals, and the Spanish Child Psychiatry Association. Dr. Joshi has received research support from Abbott, Bristol Myers Squibb, Cephalon, Eli Lilly and Co., GlaxoSmithKline, Johnson and Johnson, McNeil, Merck, the National Institute of Mental Health, New River, Novartis, Organon, Otsuka, Takeda, Pfizer, and Shire. He is a member of the National Institute of Mental Health Editorial Board. He has received the Ethel DuPont Fellowship Award. He has received the Pilot Research Award from the American Academy of Child and Adolescent Psychiatry. Ms. Martelon, Mr. Bateman, Ms. Fried, and Mr. Petty report no biomedical financial interests or potential conflicts of interest.